Retour sur lavenir.net
   ACKERMANS V.HAAREN 284.800 € (-0,77 %)     AB INBEV 74.680 € (+1,22 %)     ARGENX SE 784.400 € (+0,33 %)     UMICORE 20.820 € (-2,25 %)     VASTNED 29.750 € (+0,34 %)     KBC ANCORA 80.900 € (+0,62 %)     IBA 16.760 € (+0,60 %)     KBC 117.250 € (-0,51 %)     ELIA GROUP 138.500 € (-0,86 %)     WDP 22.520 € (+1,08 %)     HOME INVEST BE. 19.300 € (-0,21 %)     AZELIS GROUP 9.910 € (-0,10 %)     WHAT'S COOKING GP 144.500 € (0,00 %)     EVS 27.700 € (-0,72 %)     SYENSQO 66.800 € (-0,30 %)     BPOST 1.552 € (-0,51 %)     TITAN S.A. 52.500 € (-1,50 %)     MONTEA 67.200 € (+1,66 %)     MELEXIS 76.400 € (-3,41 %)     GIMV 45.150 € (+2,03 %)     SHURGARD 25.750 € (+0,98 %)     CENERGY 23.300 € (-3,80 %)     KINEPOLIS GROUP 36.500 € (+2,38 %)     JENSEN-GROUP 84.200 € (+1,45 %)     ORANGE BELGIUM 21.500 € (0,00 %)     SIPEF 92.900 € (+0,32 %)     CIE BOIS SAUVAGE 302.000 € (0,00 %)     FLUXYS BELGIUM D 19.500 € (+0,26 %)     RETAIL ESTATES 70.100 € (+0,43 %)     ATENOR 1.690 € (-3,43 %)     FAGRON 23.800 € (-0,63 %)     ACCENTIS 0.026 € (-1,89 %)     BEKAERT 39.500 € (-1,86 %)     XIOR 26.700 € (+1,14 %)     WERELDHAVE BELGIUM 52.800 € (+0,76 %)     PROXIMUS 6.085 € (-0,33 %)     D'IETEREN GROUP 170.500 € (-1,73 %)     TINC 11.380 € (0,00 %)     SOFINA 220.200 € (+0,46 %)     ONWARD MEDICAL 2.640 € (+0,96 %)     ECONOCOM GROUP 1.515 € (+1,68 %)     GBL 78.950 € (-0,19 %)     RECTICEL 10.740 € (-1,10 %)     NYXOAH 1.530 € (+3,66 %)     AGEAS 69.750 € (+0,50 %)     AGFA-GEVAERT 0.423 € (-1,40 %)     COFINIMMO 84.500 € (+1,62 %)     CARE PROPERTY INV. 12.600 € (+0,48 %)     LOTUS BAKERIES 11 520.000 € (+0,88 %)     VGP 84.300 € (0,00 %)     VIOHALCO 19.320 € (-0,92 %)     BIOTALYS 3.120 € (-1,58 %)     ONTEX GROUP 2.525 € (+0,20 %)     TUBIZE-FIN 225.400 € (+2,55 %)     VAN DE VELDE 30.200 € (0,00 %)     CAMPINE 218.000 € (+1,87 %)     CMB.TECH 12.500 € (-4,87 %)     DECEUNINCK 2.220 € (0,00 %)     CELYAD ONCOLOGY 0.251 € (+0,40 %)     BREDERODE 104.600 € (+1,36 %)  
   NANOBIOTIX 31.080 € (+3,74 %)     SERGEFERRARI GROUP 8.000 € (+2,56 %)     TOTALENERGIES 68.360 € (-1,31 %)     SERGEFERRARI GROUP 8.000 € (+2,56 %)     ADYEN 824.900 € (+0,37 %)     EXAIL TECHNOLOGIES 116.700 € (+25,28 %)     CAPGEMINI 89.680 € (+1,33 %)     SHELL PLC 33.700 € (-1,00 %)     BUREAU VERITAS 26.120 € (+0,66 %)     HERMES INTL 1 626.000 € (+0,77 %)     PHILIPS KON 23.890 € (-0,17 %)     SANOFI 75.070 € (+1,78 %)     ASML HOLDING 1 578.200 € (-0,99 %)     BOLLORE 4.100 € (+0,15 %)     VEOLIA ENVIRON. 36.230 € (+0,22 %)     SMCP 5.015 € (+0,30 %)     FLOW TRADERS 25.580 € (-0,93 %)     ASM INTERNATIONAL 948.000 € (-4,34 %)     AYVENS 11.460 € (-0,87 %)     CSG 12.682 € (+2,69 %)     BE SEMICONDUCTOR 282.700 € (-2,21 %)     SCOR SE 31.980 € (+0,50 %)     STMICROELECTRONICS 62.580 € (-3,81 %)     ESSILORLUXOTTICA 168.650 € (+1,54 %)     CRCAM TOURAINE CCI 138.500 € (-0,93 %)     LISI 66.100 € (-0,15 %)     LVMH 495.750 € (+0,27 %)     BOUYGUES 49.750 € (-0,78 %)     DSM FIRMENICH AG 79.980 € (-0,65 %)     NEXANS 141.100 € (-3,75 %)     STELLANTIS NV 5.024 € (-1,95 %)     THALES 216.500 € (-0,87 %)     UMG 18.355 € (+0,71 %)     NN GROUP 76.320 € (-0,29 %)     AHOLD DEL 35.430 € (+0,85 %)     2CRSI 27.520 € (+8,01 %)     SODEXO 51.250 € (-0,10 %)     SOITEC 114.350 € (+1,87 %)     TKH GROUP 43.620 € (+1,73 %)     LNA SANTE 34.000 € (+3,03 %)     OVH 13.600 € (+1,49 %)     BAM GROEP KON 12.550 € (-1,18 %)     AMG 32.900 € (-1,56 %)     EUROFINS SCIENT. 68.960 € (+1,00 %)     CEGEDIM 11.040 € (-1,43 %)     AALBERTS NV 38.980 € (-1,66 %)     DANONE 72.120 € (+3,06 %)     ALSTOM 15.380 € (-1,94 %)     REXEL 36.860 € (-1,18 %)     RELX 27.440 € (-0,29 %)     HAFFNER ENERGY 0.217 € (-2,25 %)     ERAMET 45.160 € (-1,40 %)     SAINT GOBAIN 80.600 € (-1,42 %)     BNP PARIBAS ACT.A 101.120 € (-1,83 %)     RUBIS 31.540 € (+0,64 %)     JCDECAUX 19.050 € (+1,33 %)     PERNOD RICARD 65.960 € (-0,06 %)     SAVENCIA 66.600 € (0,00 %)     AIRBUS 191.900 € (-1,63 %)     ALTEN 53.400 € (+1,81 %)  
News Réglementées
27/06/2026 00:05

EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss

EQS-News: EAN Congress / Key word(s): Miscellaneous
EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss

27.06.2026 / 00:05 CET/CEST
The issuer is solely responsible for the content of this announcement.


GENEVA, June 27, 2026 /PRNewswire/ -- Adults with both epilepsy and hearing loss who use hearing aids may have a 23% lower risk of developing dementia than those who do not, according to new research presented at the European Academy of Neurology (EAN) Congress 2026.

Hearing loss is widely recognised as the largest modifiable risk factor for dementia. Yet whether hearing aids can reduce dementia risk remains debated.

To explore this, researchers from University Hospital Zurich and the University of Liverpool analysed electronic health records from more than 250 million patients in the TriNetX network.

They compared adults with hearing loss who used hearing aids with closely matched adults who did not. The analysis included the overall hearing-loss population as well as people living with epilepsy, stroke, type 2 diabetes, chronic kidney disease, heart failure, migraine and osteoarthritis.

No significant association was found between hearing aid use and dementia risk in the overall population with hearing loss, nor among people with stroke, migraine, type 2 diabetes, chronic kidney disease, heart failure or osteoarthritis.

However, among adults with both epilepsy and hearing loss, hearing aid use was associated with a 23% lower risk of dementia. This corresponded to an absolute risk reduction of 2.7 percentage points over five years, equivalent to one fewer case of dementia for every 37 people using hearing aids.

The researchers believe the findings may be explained by differences in cognitive reserve – the brain's ability to continue functioning effectively despite age-related changes or damage caused by disease.

Lead author Dr Carolina Ferreira-Atuesta explained: "Most people with hearing loss have enough cognitive reserve to absorb the extra effort caused by hearing impairment, so correcting it may not have a large effect on dementia risk. Epilepsy is different because cognitive reserve is often already reduced, meaning that removing one additional source of strain may have a greater impact."

"There are several biologically plausible reasons why we might see this effect in epilepsy. The condition is associated with accelerated cognitive decline, temporal lobe epilepsy affects areas of the brain involved in hearing and some anti-seizure medications may worsen hearing," added Dr Ferreira-Atuesta.

The findings have important implications for clinical practice, according to the researchers. Since people with epilepsy are already in regular contact with healthcare services, hearing assessments could be readily incorporated into routine care.

Cision View original content:https://www.prnewswire.co.uk/news-releases/ean-congress-hearing-aid-use-linked-to-23-lower-dementia-risk-in-people-with-both-epilepsy-and-hearing-loss-302807678.html

rt.gif?NewsItemId=EN90015&Transmission_Id=202606261801PR_NEWS_EURO_ND__EN90015&DateId=20260626


27.06.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2355238  27.06.2026 CET/CEST

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière